Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

GW Pharmaceuticals Plc GWPHV



NDAQ:GWPHV - Post by User

GW Pharmaceuticals Plc > Someone Explain this Company
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by ScreenName1on Nov 05, 2017 12:41pm
295 Views
Post# 26908418

RE:Someone Explain this Company

RE:Someone Explain this CompanyI understand where you're coming from, I even place an order to sell half of my GW to purchase more LXRP. Then I came across this article and it looks like there could be a catalyst coming in about 50 days from now or possibly sooner. I'm holding GW and re-evaluating my decision to purchase additional LXRP. 

https://www.thecannabist.co/2017/11/03/cbd-epidiolex-fda-nda-gw-pharmaceuticals-pharmaceutical-drug/91562/

Time will tell what the best decision is. Good luck.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities